Nash/Mash Treatment Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):– https://datamintelligence.com/download-sample/nash/mash-treatment-market?an

In the global NASH/MASH treatment market, Rezdiffra generated US$62.2 million in Q3 after its launch in April 2024. If the European launch becomes successful in 2H of 2025, Rezdiffra is expected to generate sales of nearly 600 million in the year. DataM estimates that the drug is expected to reach US$4.5 to 5 billion in sales by 2031.

List of the Key Players in the  Nash/Mash Treatment Market:

Ipsen Pharma, Madrigal Pharmaceuticals, Zydus Therapeutics Inc., Gleason Healthcare, Novo Nordisk A/S, Eli Lilly and Company, 89bio, Inc., Boehringer Ingelheim International GmbH, Akero Therapeutics, Inc. and NeuroBo Pharmaceuticals, Inc. among others.

Emerging Players 

Viking Therapeutics, ICON plc, FOMAT Medical Research INC. among others.

Industry Development:

In October 2024, Boehringer Ingelheim announced that the U.S. FDA granted Breakthrough Therapy designation to survodutide (BI 456906), a dual glucagon/GLP-1 receptor agonist, for treating adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced fibrosis (stages 2 or 3).

Growth Forecast Projected:

The Global  Nash/Mash Treatment Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Nash/Mash Treatment Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Segment Covered in the  Nash/Mash Treatment Market:

By Drug Type: Marketed Drugs, Rezdiffra , Saroglitazar, Emerging DrugsCenicriviroc (CVC) , Elafibranor, Semaglutide , Others

By Distribution Channel: Hospital Pharmacies, Online Pharmacies , Retail Pharmacies

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com 
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com